Gastrointestinal cancer-associated fibroblasts expressing Junctional Adhesion Molecule-A are amenable to infection by oncolytic reovirus.
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
18
03
2022
accepted:
06
07
2022
revised:
13
06
2022
pubmed:
23
7
2022
medline:
17
12
2022
entrez:
22
7
2022
Statut:
ppublish
Résumé
Gastrointestinal (GI) cancers are characterized by extensive tumor stroma that both promotes tumor progression and acts as a physical barrier for adjacent tumor cells, limiting the effect of current treatment modalities. Oncolytic virotherapy is currently investigated in clinical trials as a novel therapeutic agent for different malignancies of the GI tract, but it is largely unknown whether these viruses can also target the tumor stroma. Here, we investigated the tropism of two commonly studied OVs, adenovirus and reovirus, towards primary GI fibroblasts from human oesophageal, gastric, duodenal and pancreatic carcinomas (N = 36). GI fibroblasts were susceptible to type 3 Dearing (T3D) strain R124 and bioselected mutant reovirus (jin-3) infection but not oncolytic adenovirus (Ad5-Δ24). Efficient infection and apoptosis of human and mouse GI cancer-derived fibroblasts by these reoviruses was partially dependent on the expression of the reovirus entry receptor, Junctional Adhesion Molecule-A (JAM-A). Moreover, human GI cancer organoid-fibroblast co-cultures showed higher overall infectivity when containing JAM-A expressing fibroblasts as compared to JAM-A negative fibroblasts, indicating a potential role of JAM-A expressing fibroblasts for viral dissemination. We further show that JAM-A is not only necessary for efficient reovirus infection of fibroblasts but also partially mediates reovirus-induced apoptosis, dependent on signaling through the C-terminal PDZ-domain of JAM-A. Altogether, our data show the presence of JAM-A expressing fibroblasts in both human and murine GI cancers that are amenable to infection and induction of apoptosis by reovirus, extending the potential anti-cancer actions of reovirus with stromal targeting.
Identifiants
pubmed: 35869278
doi: 10.1038/s41417-022-00507-9
pii: 10.1038/s41417-022-00507-9
pmc: PMC9750869
doi:
Substances chimiques
Junctional Adhesion Molecule A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1918-1929Informations de copyright
© 2022. The Author(s).
Références
Circulation. 2014 Jan 7;129(1):66-76
pubmed: 24065611
Nat Med. 2015 May;21(5):530-6
pubmed: 25894825
Int J Pharm. 2021 Dec 15;610:121269
pubmed: 34748806
Oncogene. 2000 Jan 6;19(1):2-12
pubmed: 10644974
Onco Targets Ther. 2021 Oct 29;14:5205-5220
pubmed: 34744438
Cancer Gene Ther. 2014 Feb;21(2):68-73
pubmed: 24434571
Blood. 2007 Sep 15;110(6):1848-56
pubmed: 17505016
J Immunother Cancer. 2019 Jan 25;7(1):19
pubmed: 30683154
PLoS One. 2012;7(10):e48064
pubmed: 23110175
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33046622
PLoS One. 2013 Nov 12;8(11):e79173
pubmed: 24265754
Front Oncol. 2017 Sep 11;7:202
pubmed: 28955655
Biochim Biophys Acta Biomembr. 2020 Sep 1;1862(9):183299
pubmed: 32247783
PLoS Pathog. 2008 Dec;4(12):e1000235
pubmed: 19079583
J Oncol. 2019 Nov 22;2019:6240505
pubmed: 31885581
J Virol. 2006 Feb;80(3):1261-70
pubmed: 16415003
Cell Commun Adhes. 2006 Jul-Aug;13(4):233-47
pubmed: 16916751
Cell. 1989 Jan 13;56(1):67-75
pubmed: 2521301
J Virol. 1998 Nov;72(11):8463-71
pubmed: 9765382
EMBO J. 1998 Jun 15;17(12):3351-62
pubmed: 9628872
Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10634-9
pubmed: 16027360
Annu Rev Virol. 2016 Sep 29;3(1):533-553
pubmed: 27501259
Oncolytic Virother. 2018 Mar 23;7:13-24
pubmed: 29616200
Am J Pathol. 2009 Aug;175(2):636-48
pubmed: 19608876
Mol Cancer Res. 2017 Oct;15(10):1410-1420
pubmed: 28679779
Gene Ther. 2008 Dec;15(24):1567-78
pubmed: 18650851
Br J Cancer. 2012 Apr 24;106(9):1495-8
pubmed: 22472880
J Clin Microbiol. 2013 Sep;51(9):3047-54
pubmed: 23850952
Curr Opin Cell Biol. 2009 Oct;21(5):701-7
pubmed: 19608396
J Control Release. 2014 Oct 28;192:148-56
pubmed: 25037019
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Cell. 2001 Feb 9;104(3):441-51
pubmed: 11239401
Int J Cancer. 2009 Sep 15;125(6):1343-51
pubmed: 19533747
J Virol. 2006 Mar;80(6):2760-70
pubmed: 16501085
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Cancer Res. 2018 Dec 15;78(24):6852-6865
pubmed: 30449733
Cell. 2012 Jan 20;148(1-2):213-27
pubmed: 22265413
J Virol. 2017 Feb 28;91(6):
pubmed: 28077640
Gastro Hep Adv. 2022;1(4):678-681
pubmed: 35937541
Biomedicines. 2020 Nov 05;8(11):
pubmed: 33167307
J Vis Exp. 2009 May 11;(27):
pubmed: 19488024
Exp Cell Res. 2010 Oct 15;316(17):2713-22
pubmed: 20451516
Cancer Gene Ther. 2019 Sep;26(9-10):268-281
pubmed: 30467340
Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5322-7
pubmed: 22421439
J Virol. 1991 Dec;65(12):6772-81
pubmed: 1719233
Nat Rev Drug Discov. 2015 Sep;14(9):642-62
pubmed: 26323545